Castle Biosciences to Release Second Quarter 2026 Financial Results and Host Webcast on Thursday, July 30, 2026
Castle Biosciences (Nasdaq:CSTL) will release its second quarter 2026 financial results after the market close on Thursday, July 30, 2026.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Castle Biosciences (Nasdaq:CSTL) will release its second quarter 2026 financial results after the market close on Thursday, July 30, 2026. Company management will host a webcast at 4:30 p.m. Eastern time to discuss the results, followed by a Q&A session.
Details
News Market Reaction – CSTL
On Jul 9, the day this news came out, CSTL closed 3.89% above the previous close. Our momentum scanner recorded 4 alerts for this stock that day.
Data tracked by StockTitan Argus for the Jul 9 session.
Key Figures
- Quarter end date
- June 30, 2026
- Second quarter 2026 reporting period
- Earnings release date
- July 30, 2026
- 2Q 2026 results after market close
- Webcast time
- 4:30 p.m. Eastern time
- 2Q 2026 results webcast on July 30, 2026
- Webcast early access
- 10 minutes
- Recommended time to log in before webcast start
Previous Earnings date Reports
-
Announced Q1 2026 earnings release date and post-close webcast timing.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Company management will host a webcast to discuss its financial results at 4:30 p.m. Eastern time on the same day.
Webcast Details
The live webcast can be accessed here: https://event.choruscall.com/mediaframe/webcast.html?webcastid=gbu0MZxe, or via the webcast link on the Investor Relations page of the Company's website: https://ir.castlebiosciences.com/. Please access the webcast at least 10 minutes before the start time. A replay of the webcast will be available following its conclusion.
There will be a brief Question and Answer session following management commentary.
About Castle Biosciences
Castle Biosciences (Nasdaq: CSTL) is a leading diagnostics company improving health through innovative tests that guide patient care. With a primary focus in dermatologic and gastroenterological disease, we develop personalized, clinically actionable solutions that help improve disease management and patient outcomes.
We put people first—empowering patients and clinicians and informing care decisions through rigorous science and advanced molecular tests that support more confident treatment planning. To learn more, visit www.CastleBiosciences.com and connect with us on LinkedIn, Instagram, Facebook and X.
DecisionDx-Melanoma, DecisionDx-CMSeq, i31-SLNB, i31-ROR, DecisionDx-SCC, MyPath Melanoma, AdvanceAD-Tx, TissueCypher, Esopredict, DecisionDx-UM, DecisionDx-PRAME and DecisionDx-UMSeq are trademarks of Castle Biosciences, Inc.
Investor Contact:
Camilla Zuckero
czuckero@castlebiosciences.com
Media Contact:
Allison Marshall
amarshall@castlebiosciences.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/castle-biosciences-to-release-second-quarter-2026-financial-results-and-host-webcast-on-thursday-july-30-2026-302821112.html
SOURCE Castle Biosciences, Inc.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.